Allegheny County Employees’ Retirement System v. Karyopharm Therapeutics Inc.

Court: United States District Court of the District of Massachusetts
Case Number: 1:19-cv-11597
Class Period: 03/02/2017 - 02/22/2019
Case Contacts: Avi Josefson, Hannah Ross, Michael D. Blatchley, Scott R. Foglietta

Securities class action lawsuit on behalf of Allegheny County Employees’ Retirement System (“ACERS”) against Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”), and certain of the Company’s senior executives, Karyopharm’s Board of Directors, and the underwriters of the Offerings, (collectively, “Defendants”). The action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (“Exchange Act”) on behalf of investors in Karyopharm common stock during the time period of March 2, 2017 and February 22, 2019 (the “Class Period”). The action also asserts claims under Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 on behalf of all persons who purchased or otherwise acquired Karyopharm common stock in or traceable to the Company’s public offerings of common stock conducted on or around April 28, 2017 and May 7, 2018 (the “Offerings”). A copy of the Complaint is available here.

The Complaint alleges that during the Class Period, Defendants falsely represented the safety and efficacy of selinexor, a pharmaceutical drug intended for the treatment of various types of cancer that Karyopharm was in the process of developing. Specifically, Defendants’ material misrepresentations and omissions center on Defendants’ claims regarding results from clinical trials for selinexor’s treatment of patients with certain types of blood cancer. During the Class Period, Defendants claimed that selinexor studies showed that selinexor was “well-tolerated” by patients and explained that there were “no new clinically significant adverse events in the patients receiving selinexor.” The Company repeatedly touted the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile.” In reality, selinexor was unsafe with limited efficacy.

The truth was revealed on February 22, 2019, when the Federal Drug Administration (“FDA”) released a briefing document that expressed serious concerns with selinexor. Specifically, the FDA revealed that, contrary to Karyopharm’s assurances, one of the previously cancelled selinexor trials had resulted in “worse overall survival” for certain patients treated with selinexor, which “highlight[ed] the toxicity of this drug.” The FDA unambiguously concluded that “[t]reatment with selinexor is associated with significant toxicity” and has “limited efficacy.” These disclosures caused the Company’s stock price to decline from $8.97 per share to $5.07 per share, or more than 43%.

If you wish to serve as Lead Plaintiff for the Class, you must file a motion with the Court no later than September 23, 2019, which is the first business day on which the U.S. District Court for the District of Massachusetts is open that is 60 days after the publication date of July 23, 2019. Any member of the proposed Class may move the Court to serve as Lead Plaintiff through counsel of their choice. Members may also choose to do nothing and remain part of the proposed Class.

If you wish to discuss this Action or have any questions concerning your rights or interests, please contact Avi Josefson of BLB&G at 212-554-1493, or via email at

Other Cases of Interest

  • HeartWare International, Inc.
    Southern District of New York John Rizio-Hamilton, Michael D. Blatchley, Abe Alexander
  • FleetCor Technologies, Inc.
    Northern District of Georgia Katherine M. Sinderson, Scott R. Foglietta
  • Energy Transfer LP
    Eastern District of Pennsylvania John C. Browne, Michael D. Blatchley, Hannah Ross, Adam H. Wierzbowski, Mathew Hough, James M. Fee
  • CenturyLink
    District of Minnesota Michael D. Blatchley, Michael Mathai, Amanda Boitano
  • Merit Medical Systems, Inc.
    Central District of California Jonathan D. Uslaner, Michael D. Blatchley, Lauren M. Cruz, Brenna Nelinson
  • AnaptysBio, Inc.
    Southern District of California Jonathan D. Uslaner, Hannah Ross, Avi Josefson, Michael D. Blatchley
  • Quality Systems, Inc.
    Central District of California Gerald H. Silk, Avi Josefson
  • Mohawk Industries, Inc.
    Northern District of Georgia Avi Josefson, Michael D. Blatchley
  • Mattel, Inc.
    District of California, Western Division Jonathan D. Uslaner, Hannah Ross, Avi Josefson, Michael D. Blatchley
  • JELD-WEN Holding, Inc.
    Northern District of Virginia Avi Josefson, Michael D. Blatchley